IP Library Granted Patent US 7,585,964
Granted Patent B2
US 7,585,964 · App. 10/146,658 · Granted Sep 8, 2009

Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (FISH)

Assignee: Cancer Genetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,585,964
App. No.
10/146,658
Granted
Sep 8, 2009
Kind
B2
Abstract

Probes and methods of using the probes to detect chromosomal rearrangements and/or deletions are provided. The methods utilize probes that are free of repeat sequences to provide greater selectivity and sensitivity; methods for producing such probes are also disclosed. The probe sets utilized in the detection methods are designed to hybridize to chromosomes at regions outside known breakpoints, instead of spanning the breakpoint as with conventional FISH methods, and, in some instances, are further designed to bind to regions located outside the genes involved in the rearrangement. Methods utilizing probe sets with two and four colors are also described, as are automated methods for analyzing rearrangements.

Claims (26)

1. A set of probes for detecting a human reciprocal chromosomal translocation between a potential breakpoint of a first gene located on a first human chromosome and a potential breakpoint of a second gene located on a second human chromosome and the set of probes comprises first and second nucleic acid probes from human genome,

wherein:

(1) the first nucleic acid probe bears a first label and hybridizes to a first region of the first human chromosome and the first region is outside of the first gene the first region is between the first gene and the centromere of the first human chromosome, and the first region is within 1 Mb region from the potential breakpoint within the first gene;

(2) the second nucleic acid probe bears a second label and hybridizes to a second region of the human second chromosome and the second region is outside of the second gene, the second region is between the second gene and one of the telomeres of the second human chromosome, and the second region is within 1 Mb from the potential breakpoint within the second gene;

(3) the first and second labels are different,

when the first and second human chromosomes have undergone the translocation, the first and second nucleic acid probes hybridize to a derivative chromosome formed via the translocation between the potential breakpoint of the first gene located on the first human chromosome and the potential breakpoint of the second gene located on the second human chromosome, such that both the first and second labels appear on the derivative chromosome; and

(ii) when the first and second chromosomes have not undergone the translocation, the first and second nucleic acid probes hybridize to the first and second human chromosomes respectively, such that only the first label appears on the first human chromosome and only the second label appears on the second human chromosome;

and wherein:

(a) the first gene is human BCL1 gene (BCL1), the second gene is human IGH gene (IGH), the first human chromosome is human chromosome 11, the second human chromosome is human chromosome 14, and the human reciprocal chromosomal translocation is t(11;14)(q13;q32); or

(b) the first gene is human IGH gene, the second gene is human BCL-2 gene (BCL2), the first human chromosome is human chromosome 14, the second chromosome is human chromosome 18, and the human reciprocal chromosomal translocation is t(14;18)(q32;q21); or

(c) the first gene is human MYC gene (MYC), the second gene is human IGH gene, the first human chromosome is human chromosome 8, the second human chromosome is human chromosome 14, and the human reciprocal chromosomal translocation is t(8;14)(q24;q32); or

(d) the first gene is human BCR gene (BCR), the second gene is human ABL gene (ABL), the first human chromosome is human chromosome 22, the second human chromosome is human chromosome 9, and the human reciprocal chromosomal translocation is t(9;22)(q34;q11), or

(e) the first gene is human IGH gene (IGH), the second gene is human BCL1 gene (BCL1), the first human chromosome is human chromosome 14, the second human chromosome is human chromosome 11, and the human reciprocal chromosomal translocation is t(11;14)(q13;q32); or

(f) the first gene is human BCL-2 gene (BCL2), the second gene is human IGH gene, the first human chromosome is chromosome 18, the second human chromosome is human chromosome 14 and the reciprocal human chromosomal translocation is t(14;18)(q32;q21); or

(g) the first gene is human IGH gene, the second gene is human MYC gene (MYC), the first human chromosome is human chromosome 14, the second human chromosome is human chromosome 8 and the human reciprocal chromosomal translocation is t(8;14)(q24;q32); or

(h) the first gene is human ABL gene (ABL), the second gene is human BCR gene (BCR), the first human chromosome is human chromosome 9, the second human chromosome is human chromosome 22, and the human reciprocal chromosomal translocation is t(9;22)(q34;q11).

2. The set of probes of claim 1 , wherein the first region or the second region is 100-300 kb in length.

3. The set of probes of claim 1 , wherein the first region or the second region is 10-1000 kb in length.

4. The set of probes of claim 1 , wherein the first gene is human BCL1 gene (BCL1), the second gene is human IGH gene (IGH), the first human chromosome is human chromosome 11, the second human chromosome is human chromosome 14, and the human reciprocal chromosomal translocation is t(11;14)(q13;q32).

5. The set of probes of claim 1 , wherein the first gene is human IGH gene, the second gene is human BCL-2 gene (BCL2), the first human chromosome is human chromosome 14, the second chromosome is human chromosome 18, and the human reciprocal chromosomal translocation is t(14;18)(q32;q21).

6. The set of probes of claim 1 , wherein the first gene is human MYC gene (MYC), the second gene is human IGH gene, the first human chromosome is human chromosome 8, the second human chromosome is human chromosome 14, and the human reciprocal chromosomal translocation is t(8;14)(q24;q32).

7. The set of probes of claim 1 , wherein the first gene is human BCR gene (BCR), the second gene is human ABL gene (ABL), the first human chromosome is human chromosome 22, the second chromosome is human chromosome 9, and the human reciprocal chromosomal translocation is t(9;22)(q34;q11).

8. The set of probes of claim 1 , wherein the first gene is human IGH gene (IGH), the second gene is human BCL1 gene (BCL1), the first human chromosome is human chromosome 14, the second human chromosome is human chromosome 11, and the human reciprocal chromosomal translocation is t(11;14)(q13;q32).

9. The set of probes of claim 1 , wherein the first gene is human BCL-2 gene (BCL2), the second gene is human IGH gene, the first human chromosome is human chromosome 18, the second human chromosome is human chromosome 14, and the reciprocal human chromosomal translocation is t(14;18)(q32;q21).

10. The set of probes of claim 1 , wherein the first gene is human IGH gene, the second gene is human MYC gene (MYC), the first human chromosome is human chromosome 14, the second human chromosome is human chromosome 8, and the human reciprocal chromosomal translocation is t(8;14)(q24;q32).

11. The set of probes of claim 1 , wherein the first gene is human ABL gene (ABL), the second gene is human BCR gene (BCR), the first human chromosome is human chromosome 9, the second human chromosome is human chromosome 22, and the human reciprocal chromosomal translocation is t(9;22)(q34;q11).

Assignments (6)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 16, 2019
From: PARTNERS FOR GROWTH IV, L.P.
To: CANCER GENETICS, INC.
Reel/Frame 049771/0446 →
SECURITY INTEREST Recorded May 1, 2017
From: CANCER GENETICS, INC.
To: PARTNERS FOR GROWTH V, L.P.
Reel/Frame 042192/0126 →
SECURITY INTEREST Recorded Mar 24, 2017
From: CANCER GENETICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 041718/0900 →
RELEASE OF PATENT ASSIGNMENT Recorded Apr 11, 2014
From: WELLS FARGO BANK, N.A.
To: CANCER GENETICS, INC.
Reel/Frame 032907/0794 →
SECURITY AGREEMENT Recorded Jul 21, 2008
From: CANCER GENETICS, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 021281/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2002
From: PALANISAMY, NALLASIVAM; CHAGANTI, RAJU S.
To: CANCER GENETICS, INC.
Reel/Frame 013192/0024 →
Continuity (4)
Provisional Application 6035719500 · Feb 13, 2002
Provisional Application 6033765300 · Nov 8, 2001
Provisional Application 6029112100 · May 14, 2001
Related Publication 20020192692A1 · Dec 19, 2002